MICOMICEN GIN 60ML 1%

MICOMICEN GINECOLOGICAL SCHEM AT 1%

active ingredients

100 ml foam at 1% contain: Active ingredient: cyclopyroxolamine g 1. Excipients with known effects: benzylic alcohol, perfume (this medicine contains an aroma that in turn contains the following allergens: linalol, cumarin, geranium, 3-Methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one and cynnamilic alcohol). For the full list of excipients, see paragraph 6.1.

Excellent

laurilsulfate of monoethanolamine, polyethyleneglycol 150 stearate, polysorbate 20, lecitindietanolamide, sodium edetate, alcohol benzig, perfume, lactic acid, purified water q.b.

Therapeutic indications

Helpful in the treatment of vulvo-vaginal infections supported by Candida.

Contraindications

Hypersensitivity or allergy already known to the preparation.

Population

It is advisable to use MICOMICEN foam 1 or 2 times a day, during treatment period with MICOMICEN ovum and/or MICOMICEN cream. They deter the external genitals with 10 cc (1 dose) of dissolved gynecological foam in water, without rinsing.

Conservation

None.

Warnings

In vaginal mycosis, a reinfection is possible by the partner (ping-pong effect). It is therefore appropriate to carry out a concomitant treatment of the partner with MICOMICEN 1% cream and/or foam. It is also recommended to refrain from sexual intercourse throughout the duration of therapy. The repeated use of the product can give rise to phenomena of sensitization. In this case, stop the use of the product and establish suitable therapy.

Interactions

Not reported in literature or detected in clinical practice.

Effects

Rarely a slight burning may occur in the first days of treatment; the eventual appearance of sensitization phenomena imposes the suspension of treatment and the adoption of adequate therapeutic measures. The frequency categories of unwanted effects are defined as follows: Very common (≥1/10); common (≥1/100, Classification for systems and organs Notable Pathologies of skin and subcutaneous tissue Erythema, encrustations, itching, rash, eczema and allergic dermatitis, even beyond the application site Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse

Overdosing

In case of accidental ingestion of MICOMICEN foam, it is suggested to implement the normal medical measures recommended in case of intoxication.

In pregnant women, the product must be used only in case of actual need and under the direct control of the Medic.

Source: Farmadati